Skip to main content
OpenTrials
Completed

NCT Number: NCT04261452

Heart Failure Worsens Muscle Strength in COPD

The combination of heart failure (HF) and chronic obstructive pulmonary disease (COPD) is highly prevalent, but underdiagnosed and poorly recognized. It has been suggested that the decline in functional capacity is associated with musculoskeletal and systemic changes than primary organ (heart and/or lung) failure. In addition, it is recognized that both diseases have several mechanisms that are responsible for musculoskeletal impairment. However, the association of reduced systemic perfusion with low oxygen content observed in the association of HF and COPD may contribute to the worsening of the components of the muscle impairment cascade. Thus, muscle strength and fatigue may not only be even more altered but may also be the main determinants of functional capacity in patients with coexistence of HF and COPD. Although many studies have evaluated the muscle performance of patients with HF or COPD, the literature did not show data on worsening due to the association of the diseases. Particularities identification of the muscle impairment in the coexistence of HF and COPD is fundamental for the development of rehabilitation strategies, mainly through physical exercise. In this line, the present study tested the hypothesis that the coexistence of HF and COPD could present lower values of strength and greater fatigue. Similarly, the muscle dysfunction degree could strongly correlate with the performance markers of the incremental or functional tests in patients with HF associated with COPD.

The study protocol was reviewed and approved by the Institutional Research Board. All subjects gave written informed consent before participating in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD CHF Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Muscle Weakness Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases Signs and Symptoms

Age range

30 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • non-cachectic sedentary patients
  • moderate-to-severe COPD according to GOLD classification (FEV1/ FVC <0.7 and predicted post-bronchodilator FEV1 between 30% and 80%)
  • no clinical or echocardiographic evidence of HF for the COPD group
  • echocardiographic evidence of HF with reduced left ventricular ejection fraction (<40%) for the overlap group
  • chronic dyspnoea (MRC scale score 2-4)
  • NYHA class 2 or 3.

Exclusion criteria

  • long-term O2 therapy
  • recent (within a year) rehabilitation program
  • osteomuscular limitation
  • type I or non-controlled type II diabetes mellitus
  • peripheral arterial disease associated with claudication
  • Patients with preserved ejection fraction HF

Treatment and study plan

Isokinetic dynamometer

Diagnostic Test

Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.

Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values.

Other names: Muscle Performance

cardiopulmonary exercise test

Diagnostic Test

All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.

The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population.

Functional Capacity Tests

Diagnostic Test

The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.

The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test.

Lung Function test

Diagnostic Test

Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a "Pitot-tube" based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery.

Doppler Echocardiography

Diagnostic Test

The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.

Anthropometry and Body Composition

Diagnostic Test

Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.

Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM).

Primary outcomes

  1. Muscle weakness

    Time frame: one week after all tests

    Muscle performance will be assessed by an isokinetic dynamometer. All data will be measured in absolute values and the percentage of predicted values for the Brazilian population.

  2. Cardiopulmonary function

    Time frame: one week after all tests

    Exercise capacity will be assessed by the cardiopulmonary test. All data will be measured in absolute values (ml/kg) and the percentage of predicted values for the Brazilian population.

  3. Clinical tests

    Time frame: one day after all tests

    Performance in clinical tests will be assessed by 6MWT and 4-min Step test. All data will be measured in absolute values.

  4. Lung Function

    Time frame: one day after all tests

    Clinical obstruction data will be assessed by total body plethysmography. All data will be measured in absolute values and percentage of predicted values for the Brazilian population.

  5. Cardiac Function

    Time frame: one day after all tests

    An echocardiogram will be performed to assess all cardiac functions. All data will be measured in the percentage of predicted values for the Brazilian population.

  6. Body composition

    Time frame: one day after all tests

    Fat-free mass will be assessed by body composition. All data will be measured in the percentage of predicted values for the Brazilian population.

Sponsors and collaborators

Lead sponsor

Mayron Faria de Oliveira

Other

Collaborators

  • Coordination for the Improvement of Higher Education Personnel

Registry information

Official study title

Heart Failure Worsens Leg Muscle Strength and Endurance in Patients With Chronic Obstructive Pulmonary Disease

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Feb 7, 2020
Registry last updated
Feb 7, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.